Doryx MPC Generic: When Will Generic Doxycycline Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Doryx MPC Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? TBD no date yet What opens the door is not settled yet
- Has the FDA approved a generic? March 1982 22 companies approved
- When does the last patent end? December 2034 4 patents listed with the FDA
- Can you buy a generic today? Yes 98 companies list one
It already is. A generic doxycycline hyclate is listed for sale by 98 companies, so ask your pharmacy whether it can fill your prescription with one.
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Doryx MPC, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Doryx MPC by the Numbers
- Reason
- Settlement between companiesThe brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
- How sure
- Not rated Too early to rate.
- Price competition
- Moderate 3 companies have filed, 1 first in line
- Brand sales
- $8M a yearSmaller seller
- FDA approved 2016 May 2016 FDA Orange Book
- Patents listed 4 last runs to December 2034 FDA Orange Book
- Generics FDA-approved 22 companies, the first approved March 1982 FDA Orange Book
- Pharmacies pay $18.18 per tablet NADAC, October 2026
- Medicare Part D spent $336.6K in 2025, for 114 people CMS Part D Spending by Drug
- Medicaid prescriptions 433 in the last four reported quarters, $450K CMS Medicaid drug utilization, to Q1 2026
Doryx MPC’s Road to a Generic
Doryx MPC has had the market to itself since the FDA approved it in May 2016 (Mayne Pharma International Pty Ltd). Its 4 listed patents run to December 2034. Generic companies have challenged its patents with the FDA since December 2008.
The brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Doryx MPC Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Doryx MPC’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 8,715,724 | The product’s formulation | February 2028 | Active |
| 9,295,652 | The product’s formulation; a way of using it (U-918) | October 2034 | Active |
| 9,511,031 | The product’s formulation | October 2034 | Active |
| 9,446,057 | The product’s formulation; a way of using it (U-918) | December 2034 | Active |
Source: FDA Orange Book, application 050795. Patent numbers open the patent on Google Patents.
Patent Challenges to Doryx MPC
The first patent challenge to Doryx MPC reached the FDA in December 2008, from one company on that first day. The FDA’s list has 6 entries for Doryx MPC, by form and strength. A first challenger began selling its generic in December 2010.
What Is a Patent Challenge?
A generic company that wants to sell its version before Doryx MPC’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Delayed-release tablets, 150 mg | December 2008 | 1 company | Head start no longer applies decided April 2020 | Not yet | Not yet | December 2022 |
| Delayed-release tablets, 75 mg and 100 mg | Before February 2009 | 1 company | First challenger eligible decided April 2020 | December 2010 | December 2010 | December 2022 |
| Delayed-release tablets, 200 mg | May 2014 | 1 company | First challenger eligible decided April 2020 | May 2016 | May 2016 | December 2022 |
| Delayed-release tablets, 80 mg | July 2015 | 1 company | Head start no longer applies decided April 2023 Earlier: first challenger eligible, April 2020 | April 2016 | Not yet | December 2022 |
| Delayed-release tablets, 50 mg | November 2015 | 1 company | First challenger eligible decided April 2020 | May 2016 | May 2016 | February 2028 |
| Delayed-release tablets, 60 mg and 120 mg | September 2017 | 1 company | Head start no longer applies decided August 2023 | Not yet | Not yet | December 2034 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Doxycycline Hyclate
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
At least 22 companies have applied to the FDA to make generic doxycycline hyclate.
First in line. One of them was first in line: the first company to challenge the brand’s patents can earn 180 days on the market before the other generics, which is why being first matters.
Generic companies have challenged Doryx MPC’s patents with the FDA since December 2008: see the patent challenges.
Approved by the FDA
The FDA has approved generic versions from 22 companies, the first in March 1982. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
For Sale in Pharmacies
Yes. A generic doxycycline hyclate is listed for sale by 98 companies. Ask your pharmacy whether it can fill your prescription with it.
A-S Medication Solutions, ab2289a5-54dd-3b00-e053-2a95a90a0de4, Acella Pharmaceuticals, LLC, Actavis Pharma, Inc., Advanced Rx Pharmacy of Tennessee, LLC, AiPing Pharmaceutical, Inc. and 34 more
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Strides Pharma Global Pte Ltd | March 1982 | EQ 50MG BASE, EQ 100MG BASE | AB |
| Actavis Laboratories Fl Inc | October 1982 | EQ 50MG BASE, EQ 100MG BASE | AB |
| Epic Pharma LLC | November 1982 | EQ 20MG BASE, EQ 50MG BASE, EQ 75MG BASE, EQ 100MG BASE, EQ 150MG BASE | AB |
| Hikma International Pharmaceuticals LLC | May 1984 | EQ 20MG BASE, EQ 50MG BASE, EQ 100MG BASE | AB |
| Chartwell Scheduled LLC | September 1984 | EQ 50MG BASE, EQ 100MG BASE | AB |
| Strides Pharma International AG | April 1986 | EQ 50MG BASE, EQ 100MG BASE | AB |
| Sun Pharmaceutical Industries Inc | July 1986 | EQ 20MG BASE, EQ 50MG BASE, EQ 100MG BASE | AB |
| Chartwell Molecular Holdings LLC | November 2005 | EQ 20MG BASE | AB |
| Pharmobedient Consulting LLC | February 2006 | EQ 20MG BASE, EQ 100MG BASE | AB |
| Actavis Elizabeth LLC | December 2011 | EQ 50MG BASE, EQ 75MG BASE, EQ 100MG BASE, EQ 200MG BASE | AB |
| Heritage Pharmaceuticals Inc Dba Avet Pharmaceuticals Inc | April 2013 | EQ 75MG BASE, EQ 100MG BASE, EQ 150MG BASE, EQ 200MG BASE | AB |
| Amneal Pharmaceuticals Holdings GmbH | June 2016 | EQ 100MG BASE | AB |
| Prinston Pharmaceutical Inc | November 2016 | EQ 50MG BASE, EQ 150MG BASE, EQ 200MG BASE | AB |
| Dr Reddys Laboratories SA | June 2017 | EQ 75MG BASE, EQ 150MG BASE | AB |
| Novel Laboratories Inc | September 2017 | EQ 100MG BASE | AB |
| Lupin Ltd | September 2017 | EQ 75MG BASE, EQ 150MG BASE | AB |
| Zydus Lifesciences Ltd | October 2017 | EQ 50MG BASE, EQ 100MG BASE | AB |
| Alembic Pharmaceuticals Ltd | June 2018 | EQ 20MG BASE, EQ 50MG BASE, EQ 75MG BASE, EQ 100MG BASE, EQ 150MG BASE, EQ 200MG BASE | AB |
| Ajanta Pharma Ltd | September 2018 | EQ 50MG BASE, EQ 75MG BASE, EQ 100MG BASE, EQ 150MG BASE | AB |
| Changzhou Pharmaceutical Factory | October 2019 | EQ 100MG BASE | AB |
| Acella Pharmaceuticals LLC | March 2020 | EQ 100MG BASE | AB |
| Macleods Pharmaceuticals Ltd | November 2025 | EQ 100MG BASE | AB |
| Mutual Pharmaceutical Co Inc discontinued | September 1982 | EQ 50MG BASE, EQ 100MG BASE | – |
| Mylan Pharmaceuticals Inc discontinued | February 1983 | EQ 100MG BASE | – |
| Watson Laboratories Inc discontinued | March 1983 | EQ 50MG BASE, EQ 100MG BASE | – |
| Heather Drug Co Inc discontinued | May 1983 | EQ 50MG BASE, EQ 100MG BASE | – |
| Par Pharmaceutical Inc discontinued | December 1983 | EQ 50MG BASE, EQ 100MG BASE | – |
| Ranbaxy Pharmaceuticals Inc discontinued | December 1983 | EQ 50MG BASE, EQ 100MG BASE | – |
| Teva Pharmaceuticals USA Inc discontinued | June 1984 | EQ 50MG BASE, EQ 100MG BASE | – |
| Superpharm Corp discontinued | October 1984 | EQ 50MG BASE, EQ 100MG BASE | – |
| Halsey Drug Co Inc discontinued | May 1985 | EQ 50MG BASE, EQ 100MG BASE | – |
| Warner Chilcott Div Warner Lambert Co discontinued | August 1985 | EQ 50MG BASE, EQ 100MG BASE | – |
| Warner Chilcott Bermuda Ltd discontinued | October 1985 | EQ 100MG BASE | – |
| Private Formulations Inc discontinued | July 1986 | EQ 50MG BASE, EQ 100MG BASE | – |
| Interpharm Inc discontinued | September 1988 | EQ 50MG BASE, EQ 100MG BASE | – |
| Pliva Inc discontinued | June 1992 | EQ 100MG BASE | – |
| Heritage Pharma Labs Inc discontinued | May 2005 | EQ 20MG BASE | – |
| Bausch Health US LLC discontinued | December 2005 | EQ 75MG BASE, EQ 100MG BASE | – |
| Impax Laboratories Inc discontinued | December 2010 | EQ 75MG BASE, EQ 100MG BASE | – |
| Rising Pharma Holding Inc discontinued | December 2010 | EQ 50MG BASE, EQ 75MG BASE, EQ 80MG BASE, EQ 100MG BASE, EQ 150MG BASE, EQ 200MG BASE | – |
| Aurobindo Pharma USA Inc discontinued | February 2012 | EQ 150MG BASE | – |
| Amneal Pharmaceuticals Co GmbH discontinued | October 2017 | EQ 75MG BASE, EQ 150MG BASE | – |
| Avet Lifesciences Ltd discontinued | November 2018 | EQ 100MG BASE | – |
| Zydus Pharmaceuticals USA Inc discontinued | December 2018 | EQ 75MG BASE, EQ 100MG BASE, EQ 150MG BASE | – |
| Apotex Inc discontinued | April 2019 | EQ 75MG BASE, EQ 150MG BASE | – |
| Zhejiang Yongtai Pharmaceutical Co Ltd discontinued | March 2020 | EQ 50MG BASE, EQ 100MG BASE | – |
| Bionpharma Inc discontinued | December 2020 | EQ 50MG BASE, EQ 100MG BASE | – |
| Oryza Pharmaceuticals Inc discontinued | March 2021 | EQ 100MG BASE | – |
| Nesher Pharmaceuticals USA LLC discontinued | November 2021 | EQ 50MG BASE, EQ 100MG BASE | – |
| Arthur Group LLC discontinued | March 2022 | EQ 100MG BASE | – |
| Amneal Eu Ltd discontinued | October 2022 | EQ 100MG BASE | – |
| Lupin Inc discontinued | August 2023 | EQ 50MG BASE, EQ 60MG BASE, EQ 75MG BASE, EQ 80MG BASE, EQ 100MG BASE, EQ 120MG BASE, EQ 150MG BASE, EQ 200MG BASE | – |
| Torrent Pharmaceuticals Ltd discontinued | April 2024 | EQ 75MG BASE, EQ 150MG BASE | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Doryx MPC Price: What Pharmacies Pay and What Generics Usually Do
What Pharmacies Pay for Doryx mpc DR 60 mg tablet
$18.18 per tablet in October 2026.
Hover over or tap anywhere on the chart to see that month’s price.
See the numbers
| Month | Pharmacies paid per tablet |
|---|---|
| October 2026 | $18.18 |
| September 2026 | $18.18 |
| August 2026 | $18.18 |
| July 2026 | $18.18 |
| June 2026 | $18.18 |
| May 2026 | $18.18 |
| April 2026 | $18.18 |
| March 2026 | $18.18 |
| February 2026 | $18.18 |
| January 2026 | $18.18 |
NADAC: the national average price retail pharmacies pay to buy the medicine (CMS survey, updated weekly), the last price of each month for one package. It is not what you pay: that depends on your insurance or discount card.
What a Generic Could Cost
How we estimate it. We start from what pharmacies pay for Doryx MPC today: $18.18 per tablet for Doryx mpc DR 60 mg tablet in October 2026, from the national NADAC survey. Then we apply the FDA’s finding of how far that price usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017). Doryx MPC has 22 companies lined up, so our estimate uses the figure for six or more companies. More companies would bring the price lower; fewer, less of a drop.
Dollar figures apply FDA’s median drops to the $18.18 pharmacies pay per tablet today. An estimate from the pattern, not a price quote: what you pay depends on your insurance or discount card.
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Doryx MPC
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Doryx MPC, before manufacturer rebates.
- $61.5K
- January to March 2026, the latest CMS has posted
For 42 people, about $1,098 per prescription fill - $336.6K
- 2025, the whole year
For 114 people, about $1,115 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $61,469 | 42 | $1,097.66 |
| 2025 | $336,588 | 114 | $1,114.53 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Doryx MPC only, so no generic is counted in it. What CMS says it is used for: This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria.
Medicaid Prescriptions by Quarter
433 prescriptions in the four quarters to Q1 2026, $450K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 47 | $42,155 |
| Q4 2025 | 77 | $78,644 |
| Q3 2025 | 146 | $163,465 |
| Q2 2025 | 163 | $165,689 |
| Q1 2025 | 203 | $210,695 |
Source: CMS Medicaid State Drug Utilization Data, over Doryx MPC’s own package codes.
Doryx MPC Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 60MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | Tablet, delayed release | Oral | May 2016 | Prescription reference product |
| EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | Tablet, delayed release | Oral | May 2016 | Discontinued reference product |
Source: FDA Orange Book, Mayne Pharma International Pty Ltd. Listed for sale today by Mayne Pharma and Mayne Pharma Commercial LLC (FDA NDC Directory).
Doryx MPC NDC Codes and Packages
Each Doryx MPC package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 51862-0559-30 | 120 mg tablet, delayed release | bottle of 30 tablets | Mayne Pharma Commercial LLC |
| 51862-0560-00 | DOXYCYCLINE HYCLATE 60 mg/1 tablet, delayed release | bottle of 6 tablets | Mayne Pharma Commercial LLC |
| 51862-0560-00 | DOXYCYCLINE HYCLATE 60 mg/1 tablet, delayed release | bottle of 6 tablets | Mayne Pharma Commercial LLC |
| 51862-0560-12 | DOXYCYCLINE HYCLATE 60 mg/1 tablet, delayed release | bottle of 120 tablets | Mayne Pharma Commercial LLC |
| 51862-0560-60 | DOXYCYCLINE HYCLATE 60 mg/1 tablet, delayed release | bottle of 60 tablets | Mayne Pharma Commercial LLC |
Source: the FDA NDC Directory, current listings only. Only packages sold under Doryx MPC’s own FDA approval (NDA 50795) are listed, never a generic. Some codes belong to companies that repackage Doryx MPC: it is the same medicine in a different package.
What a Generic Doryx MPC Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Doryx MPC
Is there a generic for Doryx MPC right now?
Yes. The FDA NDC Directory lists a generic doxycycline hyclate from 98 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Doryx MPC go generic?
It already has. The FDA NDC Directory lists a generic doxycycline hyclate from 98 companies, so ask your pharmacy whether it can fill your prescription with one.
Will generic doxycycline hyclate be the same as Doryx MPC?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. At least 22 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid over 95% less once six or more companies sold a generic, which would take the $18.18 pharmacies pay per tablet for Doryx MPC today to under $0.91. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Doryx MPC?
Yes. The FDA Orange Book lists approved generic versions from 22 companies, the first approved in March 1982: Strides Pharma Global Pte Ltd, Actavis Laboratories Fl Inc, Epic Pharma LLC, Hikma International Pharmaceuticals LLC and 18 more. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
When does the Doryx MPC patent expire?
The FDA Orange Book lists 4 patents for Doryx MPC; the last runs to December 2034. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (a date that is not known yet) weighs all of that.
Has anyone challenged the Doryx MPC patents?
Yes. The first patent challenge to Doryx MPC reached the FDA in December 2008, from one company on that first day. A first challenger began selling its generic in December 2010. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
How much does Doryx MPC cost now?
Pharmacies paid about $18.18 per tablet for Doryx mpc DR 60 mg tablet in October 2026, by the national survey of what pharmacies pay (NADAC). That is the pharmacy’s cost, not your price: what you pay depends on your insurance or discount card.
Changes to This Projection
- First generic expected a date that is not known yet on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- BunavailBuprenorphine Hydrochloride and Naloxone HydrochlorideJuly 2028
- Tobradex STDexamethasone and TobramycinAugust 2028
- LonsurfTipiracil Hydrochloride and Trifluridine2032 to 2033
- PrevymisLetermovirFebruary 2033
- YuvezziBrimonidine Tartrate and CarbacholNovember 2042
- FosrenolLanthanum CarbonateTBD no date yet
About Doryx MPC
- Generic name doxycycline hyclate
- How it is taken By mouth
- Company Mayne Pharma International Pty Ltd
- Patent challenges Since December 2008 (FDA)
- More drugs Brand-name drugs starting with D
- Have a question? A pharmacist answers, free. Ask about Doryx MPC
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, NADAC (CMS), CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.